NewsNovo
AbbVie has cleared a late-stage clinical trial for its multiple myeloma drug. The completion is a meaningful clinical milestone. What it leaves open is nearly every detail that would let observers assess what comes next.
The case for the program rests on the hurdle itself.
Late-stage trials are the final evidence-gathering stage before any regulatory review begins, and clearing one moves a drug materially forward in its development sequence. The counterargument is structural.
A successful completion tells the market the trial is done; it does not specify what the data showed or what regulatory steps AbbVie intends to take.
Keep reading